296
Views
7
CrossRef citations to date
0
Altmetric
ACTA REVIEWS

Systematic review of progesterone for the prevention of preterm birth in singleton pregnancies

, , , , , & show all
Pages 1180-1189 | Received 05 Jun 2009, Accepted 07 Aug 2009, Published online: 10 Nov 2009

References

  • Larroque B, Breart G, Kaminski M, Dehan M, Andre M, Burguet A, Survival of very preterm infants: Epipage, a population based cohort study. Arch Dis Child Fetal Neonatal Ed. 2004;89:F139–44.
  • Marret S, Ancel PY, Marpeau L, Marchand L, Pierrat V, Larroque B, Neonatal and 5-year outcomes after birth at 30-34 weeks of gestation. Obstet Gynecol. 2007;110:72–80.
  • Allin M, Rooney M, Griffiths T, Cuddy M, Wyatt J, Rifkin L, Neurological abnormalities in young adults born preterm. J Neurol Neurosurg Psychiatry. 2006;77:495–9.
  • Bhutta AT, Cleves MA, Casey PH, Cradock MM, Anand KJ Cognitive and behavioral outcomes of school-aged children who were born preterm: a meta-analysis. JAMA. 2002;288:728–37.
  • Langhoff-Roos J, Kesmodel U, Jacobsson B, Rasmussen S, Vogel I Spontaneous preterm delivery in primiparous women at low risk in Denmark: population based study. BMJ. 2006;332:937–9.
  • Romero R, Espinoza J, Kusanovic JP, Gotsch F, Hassan S, Erez O, The preterm parturition syndrome. BJOG. 2006;113:17–42.
  • Smith R, Van HD, Hirst J, Zakar T, Read M, Chan EC, Pathological interactions with the timing of birth and uterine activation. Aust N Z J Obstet Gynaecol. 2007;47:430–7.
  • Keirse MJ Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol. 1990;97:149–54.
  • Sanchez-Ramos L, Kaunitz AM, Delke I Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials. Obstet Gynecol. 2005;105:273–9.
  • Dodd JM, Flenady VJ, Cincotta R, Crowther CA Progesterone for the prevention of preterm birth: a systematic review. Obstet Gynecol. 2008;112:127–34.
  • Dodd JM, Crowther CA, Cincotta R, Flenady V, Robinson JS Progesterone supplementation for preventing preterm birth: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2005;84:526–33.
  • Mackenzie R, Walker M, Armson A, Hannah ME Progesterone for the prevention of preterm birth among women at increased risk: a systematic review and meta-analysis of randomized controlled trials. Am J Obstet Gynecol. 2006;194:1234–42.
  • Coomarasamy A, Thangaratinam S, Gee H, Khan KS Progesterone for the prevention of preterm birth: a critical evaluation of evidence. Eur J Obstet Gynecol Reprod Biol. 2006;129:111–8.
  • Dodd JM, Flenady V, Cincotta R, Crowther CA. Prenatal administration of progesterone for preventing preterm birth. Cochrane Database Syst Rev. 2006;CD004947.
  • Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348:2379–85.
  • da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2003;188:419–24.
  • Astle S, Slater DM, Thornton S The involvement of progesterone in the onset of human labour. Eur J Obstet Gynecol Reprod Biol. 2003;108:177–81.
  • Patel FA CJ. Prostaglandins and uterine activity. In: Smith R (ed). The endocrinology of parturition. Basic science and clinical application. Frontiers of hormone research. Basel: Karger, 2001.
  • Smith R Parturition. N Engl J Med. 2007;356:271–83.
  • Word RA, Li XH, Hnat M, Carrick K Dynamics of cervical remodeling during pregnancy and parturition: mechanisms and current concepts. Semin Reprod Med. 2007;25:69–79.
  • Lin TJ, Billiar RB, Little B Metabolic clearance of progesterone in the menstrual cycle. J Clin Endocrinol Metab. 1972;35:879–86.
  • Tulchinsky D, Okada DM Hormones in human pregnancy. IV. Plasma progesterone. Am J Obstet Gynecol. 1975;121:293–9.
  • Papiernik-Berkhauer E Étude en double aveugle d’un médicament prévenant la survenue prématurée de l’accouchement chez les femmes ‘à risque élevé’ d’accouchement prématuré. Edition Schering, Série IV. 1970;3:65–68.
  • Loudon JA, Elliott CL, Hills F, Bennett PR Progesterone represses interleukin-8 and cyclo-oxygenase-2 in human lower segment fibroblast cells and amnion epithelial cells. Biol Reprod. 2003;69:331–7.
  • Ruddock NK, Shi SQ, Jain S, Moore G, Hankins GD, Romero R, Progesterone, but not 17-alpha-hydroxyprogesterone caproate, inhibits human myometrial contractions. Am J Obstet Gynecol. 2008;199:391–7.
  • Christian MS, Brent RL, Calda P Embryo-fetal toxicity signals for 17alpha-hydroxyprogesterone caproate in high-risk pregnancies: a review of the non-clinical literature for embryo-fetal toxicity with progestins. J Matern Fetal Neonatal Med. 2007;20:89–112.
  • Katz Z, Lancet M, Skornik J, Chemke J, Mogilner BM, Klinberg M Teratogenicity of progestogens given during the first trimester of pregnancy. Obstet Gynecol. 1985;65:775–80.
  • Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril. 1994;62:485–90.
  • Stanczyk FZ Pharmacokinetics of progesterone administered by the oral and parenteral routes. J Reprod Med. 1999;44:141–7.
  • Benifla JL, Dumont M, Levardon M, Foucher E, Cadiot G, Crenn-Hebert C, Effects of micronized natural progesterone on the liver during the third trimester of pregnancy. Contracept Fertil Sex. 1997;25:165–9.
  • Erny R, Pigne A, Prouvost C, Gamerre M, Malet C, Serment H, The effects of oral administration of progesterone for premature labor. Am J Obstet Gynecol. 1986;154:525–9.
  • Noblot G, Audra P, Dargent D, Faguer B, Mellier G The use of micronized progesterone in the treatment of menace of preterm delivery. Eur J Obstet Gynecol Reprod Biol. 1991;40:203–9.
  • O’Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007;30:687–96.
  • Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med. 2007;357:462–9.
  • DeFranco EA, O’Brien JM, Adair CD, Lewis DF, Hall DR, Fusey S, Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007;30:697–705.
  • Rai P, Rajaram S, Goel N, Ayalur GR, Agarwal R, Mehta S Oral micronized progesterone for prevention of preterm birth. Int J Gynaecol Obstet. 2009;104:40–3.
  • Johnson JW, Austin KL, Jones GS, Davis GH, King TM Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med. 1975;293:675–80.
  • Facchinetti F, Paganelli S, Comitini G, Dante G, Volpe A Cervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 2007;196:453–4.
  • American College of Obstetricians and Gynecologists. ACOG Committee Opinion number 419, October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth. Obstet Gynecol. 2008;112:963–5.
  • Rebarber A, Istwan NB, Russo-Stieglitz K, Cleary-Goldman J, Rhea DJ, Stanziano GJ, Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Diabetes Care. 2007;30:2277–80.
  • Spong CY, Meis PJ, Thom EA, Sibai B, Dombrowski MP, Moawad AH, Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. Am J Obstet Gynecol. 2005;193:1127–31.
  • Jayasooriya GS, Lamont RF The use of progesterone and other progestational agents to prevent spontaneous preterm labour and preterm birth. Expert Opin Pharmacother. 2009;10:1007–16.
  • Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev. 2008;CD003511.
  • Northen AT, Norman GS, Anderson K, Moseley L, Divito M, Cotroneo M, Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol. 2007;110:865–72.
  • Raman-Wilms L, Tseng AL, Wighardt S, Einarson TR, Koren G Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. Obstet Gynecol. 1995;85:141–9.
  • Reinisch JM, Ziemba-Davis M, Sanders SA Hormonal contributions to sexually dimorphic behavioral development in humans. Psychoneuroendocrinology. 1991;16:213–78.
  • Berghella V, Odibo AO, To MS, Rust OA, Althuisius SM Cerclage for short cervix on ultrasonography: meta-analysis of trials using individual patient-level data. Obstet Gynecol. 2005;106:181–9.
  • Bailit JL, Votruba ME Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 2007;196:219.e1–7.
  • Odibo AO, Stamilio DM, Macones GA, Polsky D 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: a cost-effectiveness analysis. Obstet Gynecol. 2006;108:492–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.